Skip to main content

Recent Advances in Soft Tissue Tumor Pathology: Evolving Classification, Novel Molecular Findings and New Diagnostic Markers

Evaluated by: 
David B. Kaminsky, M.D., FIAC, December 6, 2018
Original release date: January 8, 2019
Access to this course expires on:  December 6, 2021, at 11:59 PM Pacific Time
CME 11.25

Course Description

The diagnosis of soft tissue tumors can be a significant challenge (even for experienced pathologists) because of their rarity, the broad morphological spectrum of mesenchymal tumors, and overlap with other soft tissue tumors and non-mesenchymal neoplasms. The classification of soft tissue tumors continues to evolve, following the description of “new” tumor types, the discovery of novel molecular genetic alterations, and the development of increasingly specific diagnostic immunohistochemical markers. If your specialty interest is in soft tissue pathology, or if your practice requires enhanced competency in evaluating soft tissue lesions, this course is designed to familiarize you with recently-described soft tissue tumors and recently-developed diagnostic markers.

Target Audience
  • Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:

  • Develop a differential diagnosis for soft tissue tumors based on dominant histologic patterns and anatomic sites 
  • Apply immunohistochemistry to help resolve the differential diagnosis 
  • Understand the role of molecular genetic testing for the diagnosis of soft tissue tumors

Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 11.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Beginning in 2021, the American Board of Pathology (ABPath) will no longer require Self-Assessment Modules (SAMs) for Part II Lifelong Learning of the Continuing Certification program. For additional information, visit the ABPath website.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:  Jason L. Hornick, M.D., Ph.D., Consultant, Eli Lilly,Consultant, Epizyme

The following faculty reported no relevant financial relationships: Thomas Brenn, M.D., Ph.D., FRCPath, Sarah Dry, M.D., Karen Fritchie, M.D.

The following IM Coordinator who planned and reviewed content for this activity reported relevant financial relationships: Jason L. hornick, MD, PhD: Consultant, Eli Lilly, Epizyme

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

To earn CME credit, all learners must complete the evaluation. Your certificate will be available to view and print by clicking here.

Buy the entire Recent Advances in Soft Tissue Tumor Pathology: Evolving Classification, Novel Molecular Findings and New Diagnostic Markers course and get a great discount!

Not A Member? Click Here